enGene Appoints Goluboff Chief Medical Officer

Company enGene Event Type Chief medical officer appointment Modality Nonviral intravesical IL-12 gene therapy Asset Detalimogene voraplasmid Target Local IL-12 expression Disease Area BCG-unresponsive non-muscle-invasive bladder cancer Summary Source-gap reconciliation: enGene appointed Erik T. Goluboff chief medical officer effective November 9, succeeding William Grossman’s interim…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *